anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ME/CFS (ICD-10 G93.3) is a multisystem chronic disease that can lead to severe disability. Pre-pandemic prevalence was estimated at approximately 0.3% worldwide, and increasing prevalence is observed due to ME/CFS in the context of long-term sequelae of coronavirus diseases 2019 (COVID-19). In Germany, the number of affected people in Germany was estimated as approximately 350.000-400.000 in 2018/2019 and almost 500.000 in 2021. ME/CFS can manifest at any age, with peak prevalence in adolescents and young adults. Common triggers include COVID, influenza, and Epstein-Barr virus-associated infectious mononucleosis (EBV-IM). Non-infectious triggers are known as well. Autoimmunity and dysfunction of the autonomic nervous system (ANS) were suggested as possible pathomechanisms. Core symptoms include fatigue, post-exertional malaise (PEM), and unrefreshing sleep. Additional symptoms comprise cognitive deficits ("brain fog"), orthostatic intolerance, neuroendocrine, and immunological symptoms. ME/CFS is diagnosed according to clinical criteria (mostly criteria by the Institute of Medicine (IOM) or Canadian Consensus Criteria) and by appropriate differential diagnostics to exclude other disorders with similar symptoms. So far, no biomarker or specific therapy is available. Therapeutic approaches are holistic and aim at the palliation of symptoms as well as psychosocial support. Self-management with pacing is recommended. Knowledge of ME/CFS among healthcare providers is still scarce, and many patients do not receive adequate care.

With this web-based, German-wide registry, the investigators aim at deep phenotyping of the disease, identification of subtypes and risk factors, describing trajectories of the disease and patient journeys, and providing clinical data for future clinical trials. Patients are also invited to contribute biosamples for future translational research.
Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks.
BACKGROUND: 3D-Slicer is an open-source medical image processing and visualization software. In the surgical treatment of trigeminal neuralgia, it is commonly used to predict the responsible vessels. However, there are few reports on the use of 3D-Slicer software to quantitatively measure the bilateral trigeminal nerve volume in patients with primary trigeminal neuralgia (PTN) based on the three-dimensional images. Therefore, this study aims to explore the role of three-dimensional fused images processed by 3D-Slicer in the evaluation of trigeminal nerve atrophy, providing an objective basis for the diagnosis of PTN.
METHODS: 57 PTN patients who underwent microvascular decompression (MVD) or percutaneous balloon compression (PBC) surgery in Hebei general hospital between January 2020 and April 2023 were included. Additionally, 30 patients with facial spasms(HFS) were included as a control group. All patients underwent 3D-TOF-MRA and 3D-FIESTA sequence examinations. Comparisons of bilateral trigeminal nerve volumes within and between groups were conducted by performing image fusion using 3D-slicer.
RESULTS: The volume of the affected trigeminal nerve in the MVD group (33.96 mm³±12.61 mm³) and PBC group (23.05 mm³±7.71 mm³) was smaller than that of the unaffected trigeminal nerve in the MVD group (39.61 mm³±12.83 mm³) and PBC group (26.14 mm³±6.42 mm³), as well as the average volume of the trigeminal nerve in the control group (40.27 mm³±10.25 mm³) (P<0.05). The differences in bilateral trigeminal ganglion volume (∆V) was significant between the MVD group (∆V=23.59 %±14.32 %) and the control group (∆V=14.64 %±10.00 %) (P<0.05). There was no statistical difference in the trigeminal nerve volume difference between the MVD group (∆V=23.59 %±14.32 %) and the PBC group (∆V=26.52 %±15.00 %) (P>0.05).
CONCLUSION: Trigeminal nerve atrophy is correlated with primary trigeminal neuralgia. 3D-slicer software can quantitatively measure trigeminal nerve volume and assist in the diagnosis of primary trigeminal neuralgia based on the difference in bilateral trigeminal nerve volumes. However, trigeminal nerve atrophy is not associated with postoperative pain recurrence in patients.
Erythromycin, USP is produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. The base, the stearate salt, and the esters are poorly soluble in water. Erythromycin ethylsuccinate, USP is an ester of erythromycin, USP suitable for oral administration. Erythromycin ethylsuccinate, USP is known chemically as erythromycin 2'-(ethyl succinate). The molecular formula is C43H75NO16 and the molecular weight is 862.05 g/mol. The structural formula is:

Erythromycin ethylsuccinate for oral suspension, USP, 200 mg/5 mL when reconstituted with water, forms a suspension containing erythromycin ethylsuccinate, USP equivalent to 200 mg erythromycin per 5 mL (teaspoonful) or 100 mg per 2.5 mL (dropperful) with an appealing fruit flavor. Erythromycin ethylsuccinate for oral suspension, USP, 400 mg/5 mL when reconstituted with water, forms a suspension containing erythromycin ethylsuccinate, USP equivalent to 400 mg of erythromycin per 5 mL (teaspoonful) with an appealing banana flavor. 

These products are intended primarily for pediatric use but can also be used in adults. 

Inactive Ingredients

Erythromycin ethylsuccinate for oral suspension, USP, 200 mg/5 mL contains caramel flavor, mixed fruit flavor, polysorbate 80, sodium citrate dihydrate, sucrose, and xanthan gum. Erythromycin ethylsuccinate for oral suspension, USP 400 mg/5 mL contains banana flavor, caramel flavor, polysorbate 80, sodium citrate dihydrate, sucrose, and xanthan gum.
The present disclosure relates to a process for the preparation of core-shell particles by the coacervation method encapsulating contrast agents for multimodal imaging. The process consists in: a.Providing a water in oil emulsion of a biocompatible polyelectrolyte polymer. b.Providing an aqueous solution of a biocompatible polyelectrolyte polymer having opposite charges of the polyelectrolyte of step a). c.Adding a crosslinking agent to the primary emulsion and the secondary solution. d.Adding at least a tracer independently to the primary emulsion or the secondary solution or emulsion. e.Adding the secondary aqueous solution to the primary emulsions and occurring of the complex coacervation leading to the separation of the coacervate particles. f.Optionally absorb a further tracer into the nanoparticles The disclosure also relates to the coacervates obtained by the above described process and their use as probe for multimodal imaging in the diagnostic field.
The vaccine prepared is comprised of five components: a) inactivated bacteria of the genus Staphylococcus (S. aureus, strain 1A and S. simulans, strain C338) b) exotoxines of S. aureus (strain 1A) c) adjuvant dextran sulfate d) purified exopolysaccharides of S. aureus (strain C104+) and e) liposomes which contain said exopolysaccharides. The vaccine is comprised of the inoculae A and B. The components a, b and c form the inoculum A and the components d and e form the inoculum B. All the constituent strains were isolated for the vaccine. The utilization of purified exopolysaccharides and of liposomes to immunopotentiate them (inoculum B) make this vaccine efficient against mucous strains of staphylococci, while the application of inoculum A make it efficient against non mucous strains of said genus, as well as against toxines of S. aureus. Said vaccine may be applied to species of ruminants (against mammitis) and it may also be used in human beings.
Participants in this group receive cognitive training only. The length of therapy is 12 weeks; sessions are 3 times per week, each session lasts 45 minutes, and total sessions are 36.
A rat-origin polypeptide having the amino acid sequence of SEQ ID NO:2 and having a physiological activity similar to the verotoxin of enteropathogenic Escherichia coli; and a polynucleotide encoding this polypeptide and having the base sequence of SEQ ID NO:1. This polypeptide is useful in clarifying the cytotoxicity of the verotoxin and developing therapeutic methods for infection with enteropathogenic E. coli. Moreover, the physiological activity of this polypeptide closely relates to neurodegeneration as observed in motor depression and apoptosis. Thus, this polypeptide largely contributes to the clarification of the onset mechanism of neurodegenerative diseases and development of remedies therefor. Furthermore, this polypeptide occurs in vascular endothelial cells and has an effect of elevating blood pressure. Thus, it is also usable in clarifying the activity mechanism of essential hypertension and developing novel hypotensive drugs.
BACKGROUND: Avocados are a rich source of unsaturated fats and bioactives, however, their role in altering cardiometabolic risk factors is unclear.
OBJECTIVE: The aim was to review the effects of consuming diets containing avocado compared with control diets containing no or low amounts of avocado on cardiometabolic risk factors in adults who were healthy, had clinical cardiovascular disease, or were at increased risk of cardiovascular disease.
METHODS: Five electronic databases were searched (PubMed, Web of Science, Scopus, ProQuest, and a Clinical Trials Registry) along with Google Scholar to identify studies published between January 1990 and November 10, 2021. Randomized controlled trials ≥3 weeks and prospective cohort studies were included. Ten studies-9 randomized controlled trials (n = 503 participants) and 1 prospective observational study (n = 55,407)-met the inclusion criteria. Outcomes assessed by means of meta-analysis were low-density lipoprotein cholesterol (LDL-C) (primary), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Outcomes assessed by narrative review were TC to HDL-C ratio, non-HDL-C, apolipoprotein B, blood pressure, body weight, body mass index (calculated as kg/m2), waist circumference, waist-to-hip ratio, body composition, and blood glucose and insulin concentrations. Risk of bias was assessed using the Cochrane Risk of Bias tool, version 2.0 and Newcastle-Ottawa Scale; quality of evidence was examined using the Grading of Recommendations, Assessment, Development and Evaluation method. Random-effects models meta-analyses were performed when there were ≥3 studies of the same design (ie, randomized controlled trial) and reporting the same outcome. Statistical heterogeneity was assessed by calculating χ2 and I2 statistics and publication bias was assessed by funnel plots.
RESULTS: Overall, there was a small, significant reduction in TC (-5.08 mg/dL [to convert to mmol/L, divide by 38.67]; 95% CI -9.29 to -0.87 mg/dL; P = .02) in avocado vs the control groups and no significant difference in LDL-C, HDL-C, or triglycerides. Subgroup analysis demonstrated significant reductions in LDL-C (-9.4 mg/dL [to convert to mmol/L, divide by 38.67]; 95% CI -10.84 to -7.95 mg/dL; P < .00001) and TC (-7.54 mg/dL; 95% CI -9.40 to -5.68 mg/dL; P < .00001) in avocado vs control groups in hypercholesterolemic populations, and no differences were seen in normocholesterolemic populations. However, the certainty in the findings was graded as low to very low. Body weight and composition were not negatively affected by avocado consumption.
CONCLUSIONS: Avocado consumption may reduce TC and LDL-C in people with hypercholesterolemia. Avocado consumption does not negatively impact body weight. Larger, well-conducted studies are needed to have greater confidence in the role of avocado consumption on cardiovascular disease risk factors.
The present invention provides for a secure, two- way transmission of medical data over the Internet and through the hospital's firewall using push and pull mechanisms. More particularly, the present invention utilizes standard SSH technology and the rsync and scp protocols to enable secure, cost-effective data transmission over the Internet. The hospital firewall is traversed through the use of an agent located behind the hospital's firewall. The agent utilizes a push mechanism to push the raw scan data through the firewall and over the Internet to the outside third party; and the agent uses a pull mechanism to reach through the firewall and over the Internet to retrieve the data processed by the outside third party. In other words, the present invention transfers data from the hospital to the third party by initiating a data push mechanism from behind the hospital firewall; and transfers the processed data from the outside third party back into the hospital by initiating a data pull mechanism from behind the hospital firewall. The aforementioned agent acts as a broker for the foregoing data transmission and also encodes how the data should be handled once it is received on the hospital side.
OBJECTIVE: Patients with anorexia nervosa (AN) are often anxious, display inflexible behavior and disrupted reward processing. Emerging evidence suggests that gut dysbiosis in patients contributes to the disease phenotype and progression.
METHODS: In a preclinical study, we explored whether AN-derived microbiota impacts cognitive flexibility, anxiety, and dopamine signaling using fecal microbiota transplantation (FMT) in tyrosine hydroxylase-cre rats. We performed probabilistic reversal learning task (PRLT) at the baseline, after antibiotic treatment, and following FMT from patients with AN and controls. We assessed flexible behavior, task engagement, and ventral tegmental area (VTA) dopamine signaling during and in the absence of reward. Furthermore, anxiety-like behavior was evaluated with open field (OF) and elevated plus maze (EPM) tests.
RESULTS: Neither antibiotic-induced dysbiosis nor AN FMT led to significant alterations in the number of reversals or lever press strategies after reinforced or nonreinforced lever presses (win and lose-stay) in the PRLT. However, the number of initiated trials decreased after antibiotic treatment while remaining unchanged after FMT. No significant differences were observed in VTA dopamine activity, anxiety measures in the OF and EPM tests. Microbiome analysis revealed limited overlap between the microbiota of the donors and recipients.
DISCUSSION: No evidence was found that the microbiota of patients compared to controls, nor a depleted microbiome impacts cognitive flexibility. Nonetheless, antibiotic-induced dysbiosis resulted in reduced task engagement during the PRLT. The relatively low efficiency of the FMT is a limitation of our study and highlights the need for improved protocols to draw robust conclusions in future studies.
PUBLIC SIGNIFICANCE: While our study did not reveal direct impacts of AN-associated gut microbiota on cognitive flexibility or anxiety behaviors in our preclinical model, we observed a decrease in task engagement after antibiotic-induced dysbiosis, underscoring that the presence of a gut microbiome matters. Our findings underscore the need for further refinement in FMT protocols to better elucidate the complex interplay between gut microbiota and behaviors characteristic of anorexia nervosa.
Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
OBJECTIVE: To evaluate the effects of Lower Extremity - Constraint Induced Movement Therapy on gait function and balance in chronic hemiparetic patients.
METHODS: Randomized, controlled, single-blinded study. We recruited chronic post stroke patients and allocated them to Lower Extremity - Constraint Induced Movement Tharapy (LE-CIMT) or Control Group. The LE-CIMT group received this protocol 2.5 hour/day for 15 followed days, including: 1) intensive supervised training, 2) use of shaping as a strategy for motor training, and 3) application of a transfer package. The control group received conventional physiotherapy for 2.5 hours/day for 15 followed days. Outcomes were assessed at baseline, after the interventions, and after 6 months, through 6-minute walk test and Mini-Balance Evaluation Systems Test; 10-meter walk test, Timed Up and Go, 3-D gait analysis, and Lower Extremity - Motor Activity Log.
RESULTS: LE-CIMT was superior on the Assistance and confidence subscale of Lower Extremity - Motor Activity Log, Mini-BESTest and 6-minute walk test. The effect size for all outcomes was small when comparing both groups. LE-CIMT showed clinically significant differences in daily activities, balance, and gait capacity, with no clinically significant difference for spatiotemporal parameters.
CONCLUSION: The LE-CIMT protocol had positive outcomes on balance, performance, and confidence perception.
Air forces have developed several methods for reducing fatigue-related accidents. In the Israeli Air Force, the "Dead Tired" workshop was developed with the purpose of presenting aircrew with their objective performance under sleep deprivation conditions. The aim of this study was to examine the cognitive abilities of both aircrew and unmanned aerial vehicle operators, both objectively and subjectively. All Israeli aircrew and unmanned aerial vehicle operators participated in a "Dead Tired" workshop. During the workshop, the participants performed the Psychomotor Vigilance Task, a task that tests their attention abilities, while gathering information on their subjective sleepiness in the form of a Karolinska Sleepiness Scale. Data of 366 participants (25 females), of whom 187 were unmanned aerial vehicle operators and 179 were aircrew, were obtained; and the mean age was 21.8 ± 1.2 years (range 19-26 years). A significant decline in task performance was seen following 20 hr of wakefulness in both unmanned aerial vehicle operators and aircrew (p < 0.001). Unmanned aerial vehicle operators' performance was significantly better throughout the majority of the workshop (p < 0.001). Recovery after the full-night's sleep was seen for unmanned aerial vehicle operators, but not for aircrew (p = 0.008). A high correlation was seen between Psychomotor Vigilance Task performance and Karolinska Sleepiness Scale responses (correlation coefficient = 0.93). Sleep deprivation negatively impacted the performance of both groups of participants. Unmanned aerial vehicle operators were found to be more resilient to the effects of sleep deprivation and were quicker to recover in comparison to aircrew.
Postpartum dysgalactia syndrome (PDS) is a condition affecting periparturient sows, characterized by a reduction in milk and colostrum synthesis shortly after farrowing. Insufficient milk production results in substantial economic losses due to increased piglet morbidity/mortality and premature sow culling. Since PDS develops within a few days following farrowing, the study objectives were to determine if periparturient immune cell profiles and circulating biomarkers differ in sows affected by PDS. We hypothesized differences in immune cells, circulating analytes, and inflammatory markers would exist at farrowing in sows that subsequently developed PDS compared to healthy herd-mates. Thirty-six sows with PDS symptoms were matched by parity and day of lactation with 36 healthy control (CON) sows. Diagnosis of PDS (timepoint 2) occurred on average 9.25 ± 2.67 d after farrowing. Blood samples and litter weights were collected at farrowing (timepoint 1) and at the onset of clinical PDS (timepoint 2). Piglets from PDS sows had lower average daily gain and higher mortality than piglets from CON (P < 0.01). Aspartate aminotransferase was increased (20%; P ≤ 0.06) in PDS sows compared to CON at both timepoints. Additionally, blood urea nitrogen was increased in PDS sows at timepoint 1 and timepoint 2 (13%; P = 0.08 and 16%; P = 0.01, respectively). At timepoint 2, total protein, globulin, magnesium, and cholesterol were increased (P ≤ 0.03) while γ-glutamyl transferase and albumin were decreased (P ≤ 0.02) in PDS sows. Lipopolysaccharide-binding protein, an inflammatory biomarker, was increased (48%; P = 0.07) at timepoint 2 in PDS compared to CON sows. Collectively, these data indicate PDS sows have altered metabolism and appear immune activated compared to healthy herd-mates, and further investigation is needed to determine if PDS can be predicted at farrowing.
All subjects wore an eye mask and the taped leg was covered by clothes for preventing subjects and researchers from identifying different tapings due to double-blinding. Subjects layed down on the mat in a supine position with the hip flexed 30º and the knee flexed 60º. Y type tape was applied from a point 10 cm below the anterior superior iliac spine, bisected at the junction between quadriceps femoris tendon and the patella, ending at its inferior side. And another Y type tape was applied from the tibial tuberosity, bisected at the junction between patella tendon and the patella, ending at its superior side. The first 5 cm tape was not stretched and acted as the anchor. I type tapes were applied downward and inward to the superior and inferior meniscus of the patella respectively.
A System, Method, and Apparatus for Predicting Medical No-Shows and for Scheduling is provided. The system is based on a patient appointment schedule and indicators including office type, practice area, appointment type, engagement with the office leading up to appointment, and a variety of other characteristics of each patient and appointment. The indicators can be selected, weighted proportionately, and input into an algorithm for analysis and processing. The algorithm can then predict the likelihood of a no-show for the respective patient and appointment. The likelihood can then be used for scheduling to minimize the negative impact on the medical professional of the no-show. The algorithm can be used in conjunction with machine learning to improve its accuracy as it informs itself with experience and additional data points. The likelihood of a no-show can be incorporated into scheduling programs and made accessible on mobile devices, computers, and other monitoring devices.